Penack, Olaf and Marchetti, Monia and Ruutu, Tapani and Aljurf, Mahmoud and Bacigalupo, Andrea and Bonifazi, Francesca and Ciceri, Fabio and Cornelissen, Jan and Malladi, Ram and Duarte, Rafael F. and Giebel, Sebastian and Greinix, Hildegard and Holler, Ernst and Lawitschka, Anita and Mielke, Stephan and Mohty, Mohamad and Arat, Mutlu and Nagler, Arnon and Passweg, Jakob and Schoemans, Helene and Socie, Gerard and Solano, Carlos and Vrhovac, Radovan and Zeiser, Robert and Kroger, Nicolaus and Basak, Grzegorz W. (2020) Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. LANCET HAEMATOLOGY, 7 (2). E157-E167. ISSN 2352-3026
Full text not available from this repository. (Request a copy)Abstract
Graft-versus-host disease (GVHD) is a major factor contributing to mortality and morbidity after allogeneic stem-cell transplantation. Because of the small number of results from well designed, large-scale, clinical studies there is considerable variability in the prevention and treatment of GVHD worldwide. In 2014, to standardise treatment approaches the European Society of Blood and Marrow Transplantation published recommendations on the management of GVHD in the setting of HL-identical sibling or unrelated donor transplantation in adult patients with haematological malignancies. Here we update these recommendations including the results of study published after 2014. Evidence was searched in three steps: first, a widespread scan of published trials, meta-analyses, and systematic reviews; second, expert opinion was added for specific issues following several rounds of debate; and third, a refined search to target debated or rapidly updating issues. On the basis of this evidence and the 2014 recommendations, five members of the EBMT Transplant Complications Working Party created 38 statements on GVHD prophylaxis, drug management, and treatment of acute and chronic GVHD. Subsequently, they created the EBMT GVHD management recommendation expert panel by recruiting 20 experts with expertise in GVHD management. An email-based, two-round Delphi panel approach was used to manage the consensus. Modified National Comprehensive Cancer Network categories for evidence and consensus were applied to the approved statements. We reached 100% consensus for 29 recommendations and 95% consensus for nine recommendations. Key updates to these recommendations include a broader use of rabbit anti-T-cell globulin; lower steroid doses for the management of grade 2 acute GVHD with isolated skin or upper gastrointestinal tract manifestations; flu ticasone, azithromycin, and montelukast should be used for bronchiolitis obliterans syndrome; and the addition of newer treatment options for resteroid-refractory acute and chronic GVHD. In addition, we discuss specific aspects of GVHD prophylaxis and management in the setting of haploidentical transplantation and in paediatric patients, but no formal recommendations on those procedures have been provided in this Review. The European Society of Blood and Marrow Transplantation proposes to use these recommendations as a basis for the routine management of GVHD during stem-cell transplantation.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | ACUTE MYELOID-LEUKEMIA; ORAL BECLOMETHASONE DIPROPIONATE; MATCHED UNRELATED DONORS; ANTI-THYMOCYTE GLOBULIN; BONE-MARROW; PERIPHERAL-BLOOD; MYCOPHENOLATE-MOFETIL; ACUTE GVHD; POSTTRANSPLANTATION CYCLOPHOSPHAMIDE; COMPARING METHOTREXATE; |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie) |
| Depositing User: | Petra Gürster |
| Date Deposited: | 25 Mar 2021 08:53 |
| Last Modified: | 25 Mar 2021 08:53 |
| URI: | https://pred.uni-regensburg.de/id/eprint/45272 |
Actions (login required)
 |
View Item |
